Insider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells 4,000 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $5.38, for a total transaction of $21,520.00. Following the transaction, the director now owns 64,334 shares of the company’s stock, valued at approximately $346,116.92. This represents a 5.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mark Alvino also recently made the following trade(s):

• On Tuesday, January 21st, Mark Alvino sold 4,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.10, for a total transaction of $20,400.00.

Abeona Therapeutics Stock Performance

Shares of Abeona Therapeutics stock opened at $5.54 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market cap of $240.83 million, a price-to-earnings ratio of -2.06 and a beta of 1.46. The stock’s 50-day moving average is $5.73 and its 200-day moving average is $5.73. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently bought and sold shares of ABEO. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the 3rd quarter worth about $151,000. XTX Topco Ltd bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $160,000. JPMorgan Chase & Co. increased its position in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after acquiring an additional 33,831 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABEO. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. Finally, StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 9th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.